

**INDEPENDENT AUDITOR'S REPORT
To The Members of Suraksha Diagnostic Private Limited
Report on the Audit of the Standalone Financial Statements**

Qualified Opinion

We have audited the accompanying standalone financial statements of Suraksha Diagnostic Private Limited ("the Company"), which comprise the Balance Sheet as at 31 March 2023, and the Statement of Profit and Loss, and the Cash Flow Statement, and a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, except for the possible effects of the matters described in the Basis for Qualified Opinion section below, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with the Companies (Accounting Standards) Rules, 2021, as amended ("Accounting Standards") and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2023, and its profit, and its cash flows for the year ended on that date.

Basis for Qualified Opinion

1. As described in note 32 to the standalone financial statements, in contravention of the provisions of section 185 of the Act, during the year ended 31 March 2022, the Company provided a guarantee of Rs.6,700 lakh to and created a charge on certain items of Land and Building and certain items of Property Plant and Equipment (medical equipment) belonging to the Company for Rs.2,827.16 lakh and Rs.1,105.83 lakh during the years ended 31 March 2022 and 31 March 2023 respectively, in favour of a lender against loans given by the lender to the Company's Whole Time Directors. Post 31 March 2023 the Company has filed an application for compounding of the offence under section 441 of the Act which is pending adjudication and has represented that this would have no material impact on the standalone financial statements. In the absence of sufficient appropriate audit evidence supporting the Company's representation, we are unable to comment whether the adjudication may result in possible adjustments and/or disclosures in the standalone financial statements.
2. With respect to the multiple emails alleging financial fraud / liquidation of monies / money laundering by the Company / directors over the period from 2020 to 2023 described in note 39 to the standalone financial statements, we were unable to obtain sufficient appropriate audit evidence with respect to a vendor for capital goods, inter-alia its existence, validity of transactions, from whom procurements aggregated Rs. 95.77 lakh during the period from 1 April 2021 till 21 January 2024 (during the year ended 31 March 2023, Rs.20.47 lakh; from 1 April 2023 till date of the report, Rs.26.72 lakh, per information provided by the management). In view thereof, we are unable to opine on the nature of these transactions and the impact, if any, on these standalone financial statements including any prior period adjustments, other disclosures and compliances that may be required.

DHS
LLP

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibility for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules made thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our qualified opinion on the standalone financial statements.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board of Directors' report does not include the standalone and consolidated financial statements and our auditor's reports thereon. The Report of the Company's Board of Directors is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we do not and will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

When we read the Board of Directors' report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance as required under SA 720 'The Auditor's responsibilities Relating to Other Information

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, and cash flows of the Company in accordance with the Accounting Standards and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

DH
CS

Deloitte Haskins & Sells LLP

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Company's Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

DHS
LLP

- Obtain sufficient appropriate audit evidence regarding the financial information of the Company to express an opinion on the standalone financial statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities or business activities included in the standalone financial statements of which we are the independent auditors.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The comparative financial information for the year ended 31 March 2022 included in these standalone financial statements prepared in accordance with the Accounting Standards have been audited by the predecessor auditors M/s. M S K A & Associates, Chartered Accountants, who issued an unmodified opinion vide their report dated 30 September 2022

Our opinion on the standalone financial statements and our report on Other Legal and Regulatory Requirements below is not modified in respect of this matter on the comparative financial information.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit we report that:
 - a) We have sought and except for the matters described in the Basis for Qualified Opinion section above, obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) Except for the possible effects of the matters described in the Basis for Qualified Opinion section above, in our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
 - d) Except for the possible effects of the matters described in the Basis for Qualified Opinion section above, in our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act.


UP

- e) The matters described in the Basis for Qualified Opinion section above, in our opinion, may have an adverse effect on the functioning of the Company.
- f) On the basis of the written representations received from the directors as on 31 March 2023 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2023 from being appointed as a director in terms of section 164 (2) of the Act.
- g) The qualification relating to the maintenance of accounts and other matters connected therewith, are as stated in the Basis for Qualified Opinion section and in paragraph (b) above.
- h) With respect to the adequacy of the internal financial controls with reference to standalone financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A". Our report expresses qualified opinion on the operating effectiveness of the Company's internal financial controls with reference to standalone financial statements for the reasons stated therein.
- i) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the Company being a private company, section 197 of the Act related to the managerial remuneration not applicable.
- j) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its standalone financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.
 - iv. (a) The Management has represented that, to the best of it's knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
(b) The Management has represented, that, to the best of it's knowledge and belief, no funds have been received by the Company from any

DHS
ur

**Deloitte
Haskins & Sells LLP**

- person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (c) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- v. The Company has not declared or paid any dividend during the year and has not proposed final dividend for the year.
- vi. Proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 for maintaining books of account using accounting software which has a feature of recording audit trail (edit log) facility is applicable to the Company w.e.f. 1 April 2023, and accordingly, reporting under Rule 11(g) of Companies (Audit and Auditors) Rules, 2014 is not applicable for the financial year ended 31 March 2023.
2. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order.

For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No.117366W / W-100018)



Abhijit A. Damle
Partner
(Membership No. 102912)
(UDIN 24102912BKPEP7309)

Place: Kolkata
Date: 31 January 2024

**"ANNEXURE A" TO THE INDEPENDENT AUDITOR'S REPORT
(Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)**

Report on the Internal Financial Controls with reference to standalone financial statements under Clause (i) of Sub-section 3 of section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls with reference to standalone financial statements of **Suraksha Diagnostic Private Limited** ("the Company") as of 31 March 2023 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls with reference to financial statements based on the internal control with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to standalone financial statements based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the ICAI and the Standards on Auditing prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls with reference to standalone financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to standalone financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to standalone financial statements and their operating effectiveness. Our audit of internal financial controls with reference to standalone financial statements included obtaining an understanding of internal financial controls with reference to standalone financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our qualified audit opinion on the Company's internal financial controls with reference to standalone financial statements.


LP

Meaning of Internal Financial Controls with reference to standalone financial statements

A Company's internal financial control with reference to standalone financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to standalone financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with reference to standalone financial statements

Because of the inherent limitations of internal financial controls with reference to standalone financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to standalone financial statements to future periods are subject to the risk that the internal financial control with reference to standalone financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Basis for Qualified Opinion

According to the information and explanations given to us and based on our audit, the following material weaknesses have been identified in the Company's internal financial controls with reference to standalone financial statements as at 31 March 2023:

- a. The Company did not have an appropriate internal control with reference to standalone financial statements for vendor onboarding and continuance on an ongoing basis (Company being unaware of commercial and statutory matters at the vendors) which could potentially result in material misstatement in the Company's purchases.
- b. The Company's internal financial controls regarding documentation for receipt of capital goods, including material used in construction of leasehold improvements were not operating effectively which could potentially result in material misstatement in items of Property Plant and Equipment.
- c. The Company's internal financial controls relating to monitoring compliance of applicable laws and regulations were not operating effectively which could potentially result in misstatement of rates and taxes, other current liabilities and consequent disclosures in the Company's financial statements.

A 'material weakness' is a deficiency, or a combination of deficiencies, in internal financial control with reference to standalone financial statements, such that there is a reasonable possibility that a material misstatement of the company's annual financial statements will not be prevented or detected on a timely basis.

DHC
UP

Qualified Opinion

In our opinion, to the best of our information and according to the explanations given to us, except for the possible effects of the material weakness described in sub-paragraph (a) of basis for qualified opinion paragraph above, on the achievement of the objectives of the control criteria, the Company has, in all material respects, maintained adequate internal financial controls with reference to standalone financial statements as of 31 March 2023, based on the internal control with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI and except for the effects/possible effects of the material weakness described in sub-paragraphs (b) and (c) of basis for qualified opinion paragraph above on the achievement of the objectives of the control criteria, the Company's internal financial controls with reference to standalone financial statements were operating effectively as of 31 March 2023

We have considered the material weaknesses identified and reported above in determining the nature, timing, and extent of audit tests applied in our audit of the standalone financial statements of the Company, for the year ended 31 March 2023 and these material weaknesses affect our opinion on the said standalone financial statements of the Company.

For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No.117366W / W-100018)



Abhijit A. Damle
Partner
(Membership No. 102912)
(UDIN 24102912BKEPED7309)

Place: Kolkata
Date: 31 January 2024

"ANNEXURE B" TO THE INDEPENDENT AUDITORS' REPORT

(Referred to in paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of our Report of even date and to be read subject to the possible effects of the matters described in the Basis of Qualified Opinion section above and the material weaknesses described in the Basis of Qualified Opinion in our separate Report on the Internal Controls in respect of Financial Statements, as applicable)

In terms of the information and explanations sought by us and given by the Company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that –

- (i)(a) (A) Except for the possible effects of the matter stated in sub-paragraph 2 of the Basis for Qualified Opinion section of our Report on the Audit of the Standalone Financial Statements, the Company has generally maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment except that these are in the process of updation in respect of some of the assets.
- (i)(b) (B) The Company has maintained proper records showing full particulars of intangible assets. The Company has a program of verification of Property, Plant and Equipment, so as to cover all the items once every two years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, items of Property, Plant and Equipment were due for physical verification during the year and were physically verified by the management during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification except for the to the extent updation is in progress in respect of some of the assets and possible effects of matter stated in sub-paragraph 2 of the Basis for Qualified Opinion section of our Report on the Audit of the Standalone Financial Statements.
- (i)(c) Based on our examination of the registered sale deed provided to us, we report that, the title deeds of all the immovable properties (other than immovable properties where the Company is the lessee and the lease agreements are duly executed in favour of the Company), disclosed in the financial statements included in property, plant and equipment, are held in the name of the Company as at the balance sheet date.
- (i)(d) The Company has not revalued any of its Property, Plant and Equipment and intangible assets during the year.
- (i)(e) No proceedings have been initiated during the year or are pending against the Company as at 31 March 2023 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.
- (ii)(a) The inventories were physically verified during the year by the Management at reasonable intervals. In our opinion and according to the information and explanations given to us, the coverage and procedure of such verification by the Management is appropriate having regard to the size of the Company and the nature of its operations. No discrepancies of 10% or more in the aggregate for each class of inventories were noticed on such physical verification of inventories when compared with books of account.
- (ii)(b) According to the information and explanations given to us, at any point of time of the year, the Company has not been sanctioned any working capital facility in excess of five crore rupees from banks or financial institutions and hence reporting under clause (ii)(b) of the Order is not applicable.
- (iii) During the year, the Company has made investments in, granted an unsecured loan to a Limited Liability Partnership Firm (LLP) controlled by the Company and provided security to a non-banking finance company, in respect of which:

DHS
LP

**Deloitte
Haskins & Sells LLP**

(iii)(a)	Particulars (Rs. In lakh)	Loans	Guarantees	Securities
	A. Aggregate amount granted / provided during the year			
	- Subsidiaries	98.08	-	-
	- Others	-	-	1,105.83
	B. Balance outstanding as at Balance Sheet date:			
	- Subsidiaries	98.08		
	- Others	-	6,700.00	3,932.99

During the year, the Company has not provided any guarantee and granted advances in the nature of loans, secured or unsecured, to Companies, Firms, or any other parties.

(iii)(b) The investment made and the terms and conditions of the above-mentioned loan granted during the year are, in our opinion, *prima facie*, not prejudicial to the Company's interest. Considering that the guarantee in the previous year and security provided in the previous and current year and outstanding as at 31 March 2023 are not in compliance with the provisions of the Act, these are in our opinion prejudicial to the interest of the Company. Refer sub-paragraph 1 of the basis for qualified opinion paragraph in the Auditors' Report.

(iii)(c) The loan granted by the Company is for the tenure of 24 months unless demand for repayment is made by the Company. During the year, the Company has not demanded such loan. Having regard to the fact that the repayment of principal or payment of interest has not been demanded by the Company, in our opinion, the repayments of principle amounts and receipt of interest are regular.

(iii)(d) According to information and explanations given to us and based on the audit procedures performed, in respect of loans granted by the Company, there is no overdue amount remaining outstanding as at the balance sheet date.

(iii)(e) None of the loans granted by the Company have fallen due during the year.

(iii)(f) The Company has granted a loan of Rs. 98.08 lakh to its wholly owned subsidiary which is for the tenure of 24 months unless demand for repayment is made by the Company and constitutes 100% of the total loans outstanding at the balance sheet date.

(iv) The Company has complied with the provisions of sections 185 and 186 of the Companies Act, 2013 in respect of loans granted, investments made and guarantees, and securities provided, as applicable, except in respect of the following which is a non-compliance of section 185 of the Companies Act, 2013:

Particulars (Guarantee and security)	Amount as at the year end (Rs. In lakh)	Maximum Amount outstanding during the year (Rs. In lakh)	Remarks
In respect of loan taken by whole time directors of the Company	Guarantee - Rs. 6,700.00 Security - Rs. 3,931.99	Guarantee - Rs. 6,700.00 Security - Rs. 3,931.99	Refer note and 32 (i) (b) and sub-paragraph 1 of basis of qualified opinion paragraph of the Auditors' Report

(v) The Company has not accepted any deposit or amounts which are deemed to be deposits. Hence, reporting under clause (v) of paragraph 3 of the Order is not applicable.

DHS
LLP

**Deloitte
Haskins & Sells LLP**

- (vi) The maintenance of cost records has been specified by the Central Government under section 148(1) of the Companies Act, 2013 in respect of Diagnostic Services. We have broadly reviewed the books of account maintained by the Company pursuant to the Companies (Cost Records and Audit) Rules, 2014, as amended, prescribed by the Central Government for maintenance of cost records under section 148(1) of the Companies Act, 2013, and are of the opinion that, prima facie, the prescribed cost records have been made and maintained by the Company. We have, however, not made a detailed examination of the cost records with a view to determine whether they are accurate or complete.
- (vii)(a) In respect of statutory dues:
Undisputed statutory dues, including Goods and Service tax, Provident Fund, Employees' State Insurance, Income-tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, cess and other material statutory dues where applicable to the Company have been generally regularly deposited by it with the appropriate authorities in all cases during the year.
There were no undisputed amounts payable in respect of Goods and Service tax, Provident Fund, Employees' State Insurance, Income-tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, cess and other material statutory dues in arrears as at 31 March 2023 for a period of more than six months from the date they became payable.
- (vii)(b) There are no statutory dues referred in sub-clause (a) above which have not been deposited on account of disputes as on 31 March 2023.
- (viii) There were no transactions relating to previously unrecorded income that were surrendered or disclosed as income in the tax assessments under the Income Tax Act, 1961 (43 of 1961) during the year.
- (ix)(a) In our opinion, the Company has not defaulted in the repayment of loans or other borrowings or in the payment of interest thereon to any lender during the year.
- (ix)(b) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (ix)(c) To the best of our knowledge and belief, in our opinion, term loans availed by the Company were, applied by the Company during the year for the purposes for which the loans were obtained.
- (ix)(d) On an overall examination of the financial statements of the Company, funds raised on short-term basis have, prima facie, not been used during the year for long-term purposes by the Company.
- (ix)(e) On an overall examination of the financial statements of the Company, the Company has not taken any fund from any entity or person on account of or to meet the obligations of its subsidiaries.
- (ix)(f) The Company has not raised loans during the year on the pledge of securities held in its subsidiary company.
- (x)(a) The Company has not raised monies by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under clause (x)(a) of paragraph 3 of the Order is not applicable.
- (x)(b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause (x)(b) of paragraph 3 of the Order is not applicable.
- (xi)(a) We refer to matter described in sub-paragraph 2 of the Basis for Qualified Opinion section of our Report on the Audit of the Standalone Financial Statements. We have reported a


UP

Deloitte Haskins & Sells LLP

suspected fraud on the Company to the Board of Directors for transactions with a vendor for capital goods, which is not traceable at the address included in its invoices and has charged GST to the Company despite not having a GST registration. Except for this matter and the possible impact of whistleblower emails insofar as they relate to the earlier years, no fraud by the Company and no material fraud on the Company has been noticed or reported during the year.

- (xi)(b) To the best of our knowledge, no report under sub-section (12) of section 143 of the Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.
- (xi)(c) There were whistle blower complaints received by us and by the Company subsequent to the end of the year. Refer note 39 to the financial statements. We have considered the same during the course of conduct of our audit.
- (xii) The Company is not a Nidhi Company and hence reporting under clause (xii) of paragraph 3 of the Order is not applicable.
- (xiii) Except for the possible effects of the matters described in sub-paragraph 1 of Basis for Qualified Opinion section of our Report on the Audit of the Standalone Financial Statements, in our opinion, the Company is in compliance with sections 188 of the Companies Act, 2013, where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the Standalone Financial Statements as required by the applicable accounting standards. The Company is a private company and hence the provisions of section 177 of the Act are not applicable to the Company.
- (xiv)(a) In our opinion, the Company has an internal audit system commensurate with the size and nature of its business.
- (xiv)(b) We have considered, the internal audit report issued during the year and covering the period under audit.
- (xv) In our opinion, during the year the Company has not entered into any non-cash transactions with any of its directors, subsidiary or persons connected with such directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.
- (xvi)(a)
(b),(c) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934 and hence reporting under clauses (xvi)(a), (b), and (c) of paragraph 3 of the Order is not applicable.
- (xvi)(d) The Group does not have any CIC as part of the group and accordingly reporting under clause (xvi)(d) of paragraph 3 of the Order is not applicable.
- (xvii) The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.
- (xviii) There has been resignation of the statutory auditors of the Company during the year and we have taken into consideration, the issues, objections or concerns raised by the outgoing auditors.
- (xix) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its


LSP

**Deloitte
Haskins & Sells LLP**

liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

(xx)

The Company has fully spent the required amount towards Corporate Social Responsibility (CSR) and there are no unspent CSR amount for the year requiring a transfer to a Fund specified in Schedule VII to the Companies Act or special account in compliance with the provision of sub-section (6) of section 135 of the said Act. Accordingly, reporting under clause (xx) of the Order is not applicable for the year.

For **Deloitte Haskins & Sells LLP**

Chartered Accountants

(Firm's Registration No.117366W / W-100018)



Abhijit A. Damle

Partner

(Membership No. 102912)

(UDIN 24102912BKPEP7309)

Place: Kolkata

Date: 31 January 2024

Particulars	Notes	As at 31-Mar-2023	As at 31-Mar-2022
Equity and Liabilities			
Shareholders' Fund			
Share Capital	3	852.86	852.86
Reserves and Surplus	4	15,267.38	14,148.55
Total Shareholders' Fund		16,140.24	15,001.41
Liabilities			
Non - Current Liabilities			
Long-Term Borrowings	5	841.42	1,228.13
Deferred Tax Liabilities (Net)	6	818.90	1,004.71
Long-Term Provisions	7	42.70	31.14
Total Non-Current Liabilities		1,703.02	2,263.98
Current Liabilities			
Short-Term Borrowings	8	559.14	673.81
Trade Payables			
- Total outstanding dues of micro enterprises and small enterprises	9	365.20	222.51
- Total outstanding dues of creditors other than micro enterprises and small enterprises	9	1,062.32	1,164.76
Other Current Liabilities	10	826.54	628.48
Short-Term Provisions	11	7.87	120.60
Total Current Liabilities		2,821.07	2,808.16
Total Equity and Liabilities		20,664.33	20,073.55
Assets			
Non-Current Assets			
Property, Plant and Equipment	12	11,346.00	11,755.30
Intangible Assets	13	144.07	175.38
Capital Work-in-Progress	12	239.08	109.31
Non-Current Investments	14	50.00	15.50
Long-Term Loans and Advances	15	465.31	197.06
Other Non-Current Assets	16	1,744.38	5,634.81
Total Non-Current Assets		13,988.84	17,887.36
Current Assets			
Inventories	17	861.45	622.53
Trade Receivables	18	558.44	756.70
Cash and Bank Balances	19	5,196.92	283.02
Short-Term Loans and Advances	20	258.68	523.94
Total Current Assets		6,675.49	2,186.19
Total Assets		20,664.33	20,073.55

The accompanying notes are the integral part of the financial statements: 1-40

As per our report of even date

For Deloitte Haskins & Sells LLP
Chartered Accountants
ICAI Firm Registration No.117366W/W-100018



Abhijit A. Damle

Place: Kolkata
Date: 31/01/2024

for and on behalf of the Board of Directors of
Suraksha Diagnostic Private Limited



Dr Somnath Chatterjee
DIN: 00137075

Place: Kolkata
Date: 31/01/2024



Ritu Mittal
DIN: 00165886

Suraksha Diagnostic Private Limited
CIN:U85110WB2005PTC102285
Statement of Profit and Loss for the year ended March 31, 2023
(all amounts in INR Lacs, unless stated otherwise)

Particulars	Notes	For the year ended 31 March 2023	For the year ended 31 March 2022
Income			
Revenue from Operations	21	19,050.99	22,319.25
Other Income	22	282.10	230.34
Total Income		19,333.09	22,549.59
Expenses:			
Cost of Materials Consumed	23	2,875.38	6,040.49
Employee Benefits Expense	24	4,051.30	3,413.94
Finance Costs	25	178.81	210.37
Depreciation and Amortisation Expenses	26	1,558.08	1,509.13
Other Expenses	27	9,525.53	8,056.29
Total Expenses		17,989.10	19,230.22
Profit before Tax		1,343.99	3,319.37
Tax Expenses :			
Current Tax		353.76	922.47
Tax Relating to Earlier Years:		37.21	-
Deferred Tax	6	(185.81)	21.80
		205.16	944.27
Profit After Tax for the Year		1,138.83	2,375.10
Earnings per equity share (Nominal value of Rs 100/-)	28		
- Basic		165.05	344.22
- Diluted		133.53	278.49

The accompanying notes are the integral part of the financial statements 1-40

As per our report of even date

For Deloitte Haskins & Sells LLP
Chartered Accountants
ICAI Firm Registration No.117366W/W-100018



Abhijit A. Damle
Partner

Place: Kolkata
Date: 31/01/2024

for and on behalf of the Board of Directors of
Suraksha Diagnostic Private Limited



Dr Somnath Chatterjee
Director
DIN: 00137075

Ritu Mittal
Director
DIN: 00165886

Place: Kolkata
Date: 31/01/2024

Suraksha Diagnostic Private Limited
CIN:U85110WB2006PTC102265
Summary Statement of Cash Flow Statement for the year ended March 31, 2023
(all amounts in INR Lacs, unless stated otherwise)

Particulars	For the year ended 31 March 2023	For the year ended 31 March 2022
A Cash Flow From Operating Activities		
Profit before Tax	1,343.99	3,319.37
Adjustment to reconcile profit before tax to net cash flows		
Depreciation and amortisation expenses	1,558.08	1,509.13
Interest Income	(256.28)	(181.13)
Loss on Sale of Assets	160.23	141.48
Net gain on sale of current investments	-	(0.29)
Dividend income from mutual funds	-	(0.64)
Liabilities / Provisions no longer required, written back	(16.73)	(37.07)
Interest Expenses	128.96	152.56
Operating profit before working capital changes	2,919.25	4,903.41
Movement in working capital:		
(Increase) in Inventory	(38.92)	(178.02)
Decrease/(Increase) in Trade Receivables	196.27	(133.33)
Decrease/(Increase) in Loans and Advances and Other Assets	264.45	(194.36)
Increase in Trade Payables	55.99	160.17
Increase in Other Liabilities	52.80	100.85
Increase in Provisions	13.04	37.98
Cash generated from operations	3,464.88	4,876.70
Income Tax Payments (net of refunds)	716.96	443.64
Net Cash generated from operating activities	A 2,745.90	4,233.06
B Cash Flows from Investing Activities		
Purchase of property, plant and equipment and intangibles assets including capital work in progress and capital advances	(1,312.25)	(1,910.68)
Proceeds from sale of PPE and Intangible Assets	67.80	34.41
Proceeds from sale of current investments	-	541.47
Investment in Suraksha Speciality LLP	(34.50)	(5.00)
Loan given to Suraksha Speciality LLP	(95.50)	-
Dividend income from Investments	-	0.64
Investment in fixed deposits (having original maturity of more than three months)	(1,021.85)	(3,211.30)
Interest Received	197.52	161.13
Net Cash (used in) Investing activities	B (2,196.78)	(4,369.33)
C Cash flow from Financing Activities		
Repayment of Long Term Borrowings	(501.38)	258.88
Interest Paid	(128.96)	(150.17)
Net Cash (used in) / generated from Financing activities	C (630.34)	198.71
Net (decrease) in cash and cash equivalent	(A+B+C) (83.22)	(27.56)
Cash and Cash Equivalents at beginning of the year	258.02	285.58
Cash and Cash Equivalents at end of the year	174.80	258.02
Components of Cash and Cash Equivalent		
Cash in hand (including in digital form)	55.77	44.41
Balance with Bank on Current Accounts	119.03	213.61
	174.80	258.02

Note

The above Cash Flow Statement has been prepared under the "Indirect Method" as stated in Accounting Standard 3 in Cash Flow Statement prescribed under Companies Act, 2013.

As per our report of even date.

For Deloitte Haskins & Sells LLP
Chartered Accountants
ICAI Firm Registration No.117366W/W-100018



Abhijit A. Damle
Partner

Place: Kolkata
Date: 31/01/2024

for and on behalf of the Board of Directors of
Suraksha Diagnostic Private Limited



Dr. Somnath Chatterjee
Director
DIN: 00137075

Place: Kolkata
Date: 31/01/2024



Ritu Mittal
Director
DIN: 00165886

1. Reporting Entity

Suraksha Diagnostic Private Limited is private limited company domiciled in India and incorporated on March 15, 2005 under the provision of Companies Act, 1956. The Company is engaged in the business of running diagnostic centers for carrying out various pathological and radiological services.

2. Summary of significant accounting policies:

a) Basis of Preparation

These financial statements have been prepared in accordance with the generally accepted accounting principles in India (Indian GAAP) under historical cost convention on an accrual basis in compliance with all material aspects of the Accounting Standards (AS) notified under section 133 of the Companies Act, 2013 read together with Rule 7 of the Companies (Accounts) Rules 2014 and the Companies (Accounting Standard) Amendment Rules, 2016. The accounting policies applied by the Company are consistent with those used in the previous year.

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the schedule III to the Companies Act, 2013. Based on the nature of business and the time between acquisition of assets for processing and their realization in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current or non-current classification of assets and liabilities.

b) Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires management to make judgement, estimates and assumptions that affect the reported amounts of revenue, expenses, assets and liabilities and disclosure of contingent liabilities, at the end of reporting period. Actual results could differ from those estimates.

Estimates and underlying assumptions are reviewed at each balance sheet date. Any revision to accounting estimates is recognized in accordance with the requirements of the respective accounting standard.

c) Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.

Revenue from Diagnostic Services comprises of amount billed (net of discounts) in respect of tests conducted and is recognized as and when the samples are collected for the purposes of conducting the tests which usually takes not more than 48 hours.

Interest income is recognized on a time proportion basis taking into account the amount outstanding and the rate applicable.

d) Property, plant and equipment - tangible assets

Property, plant and equipment, capital work in progress are stated at cost, less accumulated depreciation and impairment loss, if any. The cost comprises purchase price, borrowing cost, if capitalization criteria are met and any cost directly attributable to bringing the asset to its working condition for its intended use which includes taxes, freight, and installation and allocated incidental expenditure during construction/ acquisition.

DHC
UP

Subsequent expenditure relating to tangible assets is capitalized only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance.

Projects under which assets are not ready for their intended use are disclosed under Capital Work-in-Progress.

Gains or losses from derecognition or sale of tangible assets are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the Statement of Profit and Loss when the asset is derecognized or sold off.

e) Depreciation on property, plant and equipment

Based on management's evaluation, useful life prescribed in Schedule II of the Companies Act, 2013 represent actual useful life of property, plant and equipment. The Company uses Straight Line to provide depreciation on different class of its property, plant and equipment.

Depreciation on addition to tangible assets is provided on pro-rata basis from the date the assets are ready for intended use. Depreciation on sale/discard from tangible assets is provided for upto the date of sale, deduction or discard of tangible assets as the case may be.

f) Intangible assets

Intangible assets acquired separately are measured on initial recognition at cost. Intangible assets are stated at cost of acquisition less accumulated amortisation and impairment loss, if any. The cost comprises purchase price and any cost directly attributable to bringing the asset to its working condition for the intended use.

Amortization of intangible assets has been calculated on straight line basis, based on management estimates, which in the opinion of the management are reflective of the estimated useful lives of the Intangible assets.

Particulars	Useful life (In years)
Computer Software	5 to 10 years

Amortization on addition to intangible assets is provided on pro-rata basis from the date the assets are ready for intended use. Amortization on sale/discard from intangible assets is provided for upto the date of sale, deduction or discard of intangible assets as the case may be.

g) Borrowing Costs

Borrowing cost includes interest, amortization of ancillary costs incurred in connection with the arrangement of borrowings and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost.

Borrowing costs that are directly attributable to the acquisition, construction or production of an asset that takes a substantial period of time to get ready for its intended use are capitalized. All other borrowing costs are recognised as expenditure in the period in which they are incurred.

h) Investments

Investments, which are readily realizable and intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as long-term investments.

DHR
UP

On initial recognition, all investments are measured at cost. The cost comprises purchase price and directly attributable acquisition charges such as brokerage, fees and duties.

Current investments are carried in the financial statements at lower of cost and fair value determined on an individual investment basis. Long-term investments are carried at cost. However, provision for diminution in value is made to recognize a decline other than temporary in the value of the long-term investments.

On disposal of an investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the Statement of Profit and Loss.

i) Foreign Currency transaction

Initial recognition:

Foreign currency transactions are recorded in the reporting currency by applying the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Conversion:

Foreign currency monetary items are reported using the closing rate. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction; non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when such values were determined.

Exchange differences:

Exchange differences arising on the settlement of monetary items or on reporting the Company's monetary items at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognised as income or as expenses in the year in which they occur.

j) Inventories:

Inventories comprises of reagents, chemicals, surgical and laboratory supplies and stores are valued at lower of cost and net realizable value.

Cost is determined on First in First out (FIFO) method. The cost of inventory comprise all costs of purchase and other costs incurred in bringing the inventories to their present location and condition.

k) Retirement and other Employee Benefits:

i. Employee benefits payable wholly within twelve months of receiving employee services are classified as short-term employee benefits. These benefits include salaries, dearness allowance, leave encashment, house rent allowance, ex-gratia and various other allowance.

ii. The Company makes defined contribution to Government Employee Provident Fund, Government Employee Pension Fund, ESI, which are recognised in the Statement of Profit and Loss on accrual basis. Such benefits are classified as Defined Contribution Schemes as the Company does not have any further obligations under these plans beyond its monthly contributions.

iii. The Company's gratuity benefit scheme is a defined benefit plan. The calculation of the Company's obligation under the plan is using the projected unit credit method. Actuarial

DHS
UP

gains and losses are recognized in the Statement of Profit and Loss in the year in which they arise.

The Company has taken up a Group Gratuity Scheme with Life Insurance Corporation of India (LIC), 'Suraksha Diagnostic Private Limited Employees' Gratuity Fund' to meet its obligation towards gratuity. The contributions made to the Fund are recognized as plan assets. The gratuity benefit obligation recognized in the balance sheet represents the present value of the defined benefit obligation as reduced by the fair value of plan assets.

- iv. Accumulated leave, which is expected to be utilized within next 12 months, is treated as short term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

l) Impairment of Assets

The carrying amounts of assets are reviewed at each balance sheet date to determine if there is any indication of impairment based on internal/external factors. An impairment loss is recognized wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the higher of the assets' net selling price and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value at the weighted average cost of capital.

After impairment, depreciation/amortization is provided on the revised carrying amount of the asset over its remaining useful life.

m) Provision, Contingent Liability and Contingent Assets

The Company creates a provision when there is present obligation as a result of a past event that probably requires an outflow of resources and a reliable estimate can be made of the amount of obligation.

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that probably will not require an outflow of resources or where a reliable estimate of the obligation cannot be made. Contingent assets are neither recorded nor disclosed in the financial statements.

n) Taxation

Tax expense for the period comprises of current tax and deferred tax.

Provision for current tax is generally made on the basis of estimated taxable income for the current accounting year in accordance with the Income-tax Act, 1961.

Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognised amounts, and there is an intention to settle the asset and the liability on a net basis.

The deferred tax for timing differences between the book and tax profits for the year is accounted for, using the tax rates and laws that have been substantively enacted as of the reporting date.

Deferred tax charge or credit reflects the tax effects of timing differences between accounting income and taxable income for the period. The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognised using the tax rates that have been enacted or substantively enacted by the balance sheet date. Deferred tax assets are recognised only to the extent there is reasonable certainty that the assets can be realised in future; however, where there is unabsorbed depreciation or carry forward of losses, deferred tax assets are recognised only if there is a virtual certainty of realisation of such assets. Deferred tax assets are reviewed at each balance sheet date and are written-down or

written up to reflect the amount that is reasonably/virtually certain (as the case may be) to be realised.

At each reporting date, the Company reassesses the unrecognized deferred tax assets, if any.

o) Leases

As a Lessee:

Operating Leases

Leases, where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item, are classified as operating leases. Operating lease payments are recognized as an expense in the Statement of Profit and Loss on a straight-line basis over the lease term.

p) Earnings per Share

Basic earnings per share are calculated by dividing the net profit or loss after tax for the period attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the period.

The weighted average numbers of equity shares are adjusted for events such as bonus issue, bonus element in the rights issue, share split and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

q) Cash and Cash Equivalents

Cash and cash equivalents for the purpose of cash flow statement comprise of cash at bank and in hand and short-term investments with an original maturity of three months or less.

r) All amounts disclosed in the standalone financial statements and notes have been rounded off to the nearest lacs as per the requirements of the Schedule III, unless otherwise stated. Any amount appearing as Rs.0.00 represents less than Rs.500/-.

DHC
UJ

3. Share capital

Particulars	As at March 31, 2023	As at March 31, 2022
Authorised :		
12,20,000 equity shares of Rs. 100/- each	1,220.00	1,220.00
1,80,000 0.0001% Compulsorily Convertible Preference Shares of Rs. 100/- each	180.00	180.00
Total	1,400.00	1,400.00
Issued Subscribed and Fully Paid Up Shares :		
Equity Share Capital		
6,90,000 Equity Shares of Rs. 100/- each	690.00	690.00
Preference Share Capital		
1,82,859 0.0001% Compulsorily Convertible Cumulative Preference Share of Rs. 100/-each	182.86	182.86
Total	872.86	872.86

(a) (i) Reconciliation of no. of equity shares & amount outstanding at the beginning and at the end of the year

Particulars	As at March 31, 2023		As at March 31, 2022	
	No. of Shares	Amount	No. of Shares	Amount
Equity Shares outstanding at the beginning of the year	6,90,000	690.00	6,90,000	690.00
Equity Shares Outstanding at the end of the year	6,90,000	690.00	6,90,000	690.00

(ii) Reconciliation of no. of preference shares outstanding at the beginning and at the end of the year

Particulars	As at March 31, 2023		As at March 31, 2022	
	No. of Shares	Amount	No. of Shares	Amount
0.0001% Compulsorily Convertible Preference Shares outstanding at the beginning of the year	1,82,859	182.86	1,82,859	182.86
0.0001% Compulsorily Convertible Preference Shares outstanding at the end of the year	1,82,859	182.86	1,82,859	182.86

(b) (i) Rights, preferences and restrictions attached to equity shares

The Company has only one class of equity share having face value of Rs. 100/- each. Each shareholder is entitled to one vote per share held. The Company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the General Meeting. The above shareholding represent the legal ownership of shares.

In the event of liquidation of the Company, the equity shareholders shall be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders. Equity Shares held by Orbimed Asia II Mauritius Limited (Formerly known as Orbimed Asia II Mauritius FDI Investments Limited) in the Company carry certain protective rights under the terms of the Shareholders Agreement.

(ii) Rights, preferences and restrictions attached to 0.0001% Compulsorily Convertible Preference Shares

Each 0.0001% Compulsorily Convertible Preference Shares has a face value of Rs. 100/- each and are convertible into 1(Crow) Equity Share of Rs. 100 each at such time as required but mandatorily convertible after 19 years. The preference shares carry a dividend of 0.0001% per annum on the face value to be paid out of profits of the Company. The preference shares were issued on 27 March 2017.

(c) (i) Details of Equity Shares held by each Shareholder holding more than 5% of the Company :

Name of Shareholder	As at March 31, 2023		As at March 31, 2022	
	No. of Shares held	% of holding	No. of Shares held	% of holding
Kishan Kumar Kejriwal	76,945	11.15%	76,945	11.15%
Dr. Somnath Chatterjee	66,000	9.57%	66,000	9.57%
Ritu Mittal	1,57,769	22.87%	1,57,769	22.87%
Satish Verma	1,33,689	19.38%	1,33,689	19.38%
Toni Investment Limited	38,512	5.58%	38,512	5.58%
Orbimed Asia II Mauritius Limited (Formerly known as Orbimed Asia II Mauritius FDI Investments Limited)	1,34,587	19.51%	1,34,587	19.51%
Total	6,07,502	88.06%	6,07,502	88.06%

(ii) Details of 0.0001% Compulsorily Convertible Preference Shares held by each Shareholder holding more than 5% of the Company :

Shareholders Name	As at March 31, 2023		As at March 31, 2022	
	No. of Shares held	% of holding	No. of Shares held	% of holding
Orbimed Asia II Mauritius Limited (Formerly known as Orbimed Asia II Mauritius FDI Investments Limited)	1,82,859	100.00%	1,82,859	100.00%
Total	1,82,859	100.00%	1,82,859	100.00%

(d) Disclosure of shareholding of promoters

Shareholders Name	As at March 31, 2023		As at March 31, 2022	
	No. of Shares held	% of holding	No. of Shares held	% of holding
Kishan Kumar Kejriwal	76,945	11.15%	76,945	11.15%
Dr. Somnath Chatterjee	66,000	9.57%	66,000	9.57%
Ritu Mittal	1,57,769	22.87%	1,57,769	22.87%
Satish Verma	1,33,689	19.38%	1,33,689	19.38%
Total	4,34,403	62.97%	4,34,403	62.97%

(e) Disclosure of % of change in shareholding of promoters

Shareholders Name	As at March 31, 2023		As at March 31, 2022	
	No. of Shares held	% of holding	No. of Shares held	% of holding
Dr. Somnath Chatterjee	-	-	10,024	2.32%
Ritu Mittal	-	-	36,108	5.25%
Satish Verma	-	-	(25,586)	(3.70%)

DH
 SP

4 Reserves and Surplus

Particulars	As at March 31, 2023	As at March 31, 2022
Securities Premium Account		
Balances at beginning of the year	4,837.09	4,837.09
Surplus in Statement of Profit and Loss :		
Balances at beginning of the year	9,311.46	6,936.36
Add: Profit for the Year	1,139.83	2,375.10
Less: Dividend to Preference Share holders	(0.50)	(0.00)
	10,450.29	9,311.46
Total	15,287.38	14,148.55

5 Long-Term Borrowings

Particulars	As at March 31, 2023	As at March 31, 2022
Secured		
Term Loan for Medical Equipments: (Refer note 5.1 below)		
From Banks	777.89	1,104.52
Car Loans: (Refer note 5.2 below)		
From Banks	25.43	19.24
From a Financial Institution	2.29	15.19
Working Capital Term Loan:		
From Banks (Refer note 5.3 below)	34.99	89.15
Total	841.42	1,228.11

5.1 Details of rate of interest, repayment and securities with respect to term loans for Medical Equipments

The aforesaid term loans are secured against the hypothecation over Medical Equipments against which such loans have been taken and Personal Guarantee of Directors. Such loans are repayable in equal monthly instalment over a period varying from 36 months to 68 months along with interest in the range of 6.90% to 9.80% p.a.

5.2 Details of rate of interest, repayment and securities with respect to Car Loans

The aforesaid term loans are secured against the hypothecation over Vehicle's against which such loans have been taken. Such loans are repayable in equal monthly instalment over a period of 36 months along with interest in the range of 7.30% to 9.75% p.a.

5.3 Details of rate of interest, repayment and securities with respect to Working Capital Term Loan

The aforesaid working capital term loan is secured and is repayable in equal monthly instalment over a period of 48 months along with interest of 8.25% p.a.

6 Deferred Tax Liabilities (Net) - Non-Current

Particulars	As at March 31, 2023	As at March 31, 2022
Deferred Tax Liability		
Temporary differences in carrying cost of PPE and Intangibles assets between books of account and tax purposes	872.73	1,062.88
Gross deferred tax liability	872.73	1,062.88
Deferred Tax Asset		
Expenses allowable on payment basis	41.10	47.55
Provision for Employee Benefits	12.73	10.62
Gross deferred tax asset	53.83	58.17
Net Deferred Tax Liabilities	818.90	1,004.71

7 Long-Term Provisions

Particulars	As at March 31, 2023	As at March 31, 2022
Provision for employee benefits		
Gratuity (Refer Note 31)	-	1.05
Defined Benefit - Leave	42.70	30.09
Total	42.70	31.14

8 Short-Term Borrowings

Particulars	As at March 31, 2023	As at March 31, 2022
Secured - Current maturities of Long Term Borrowings (Refer Note 5)		
Term Loan for Medical Equipments:		
From Banks	455.62	608.93
Car Loans:		
From Banks	5.65	2.69
From a Financial Institution	12.90	11.58
Working Capital Term Loan:		
From Banks	54.97	50.63
Total	529.14	673.83

DHS
 LLP

9 Trade payables

Particulars	As at March 31, 2023	As at March 31, 2022
Total outstanding dues of micro enterprises and small enterprises	365.20	222.51
Total outstanding dues of creditors other than micro enterprises and small enterprises	1,062.32	1,164.76
Total	1,427.52	1,387.27

Information required to be furnished as per Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006 (MSME Act) and Schedule III of the Companies Act, 2013 for the year ended March 31, 2023. This information has been determined to the extent such parties have been identified on the basis of information available with the Company and relied upon by auditors.

9.1 Information in terms of Section 22 of Micro, Small and Medium enterprises Development Act, 2006(MSMED) are given below:

Particulars	As at March 31, 2023	As at March 31, 2022
a) The Principal amount and the interest due thereon remaining unpaid to any supplier as at the end		
(i) Principal amount due remaining unpaid	365.20	222.51
(ii) Interest amount due remaining unpaid	0.04	-
b) The amount of interest paid in terms of section 16 of the MSME Act along with the amount of the payment made to the supplier beyond the appointed day during each accounting year	-	-
c) The amount of interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006	-	-
d) The amount of interest accrued and remaining unpaid at the end of each accounting year	-	-
e) The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance as a deductible expenditure under section 23 of the MSME Act.	-	-

9.2 Trade Payables Ageing Schedule

Particulars	Outstanding as on March 31, 2023 from due date of payment						Total
	Unbilled	Not Due	Upto 1 Year	1-2 years	2-3 years	More than 3 years	
Total outstanding dues of micro enterprises and small enterprises	40.58	323.16	1.39	-	0.07	-	365.20
Total outstanding dues of creditors other than micro enterprises and small enterprises	106.93	877.59	52.15	16.11	9.25	0.29	1,062.32
Total	147.51	1,200.75	53.54	16.11	9.32	0.29	1,427.52

Particulars	Outstanding as on March 31, 2022 from due date of payment						Total
	Unbilled	Not Due	Upto 1 Year	1-2 years	2-3 years	More than 3 years	
Total outstanding dues of micro enterprises and small enterprises	-	218.22	4.29	-	-	-	222.51
Total outstanding dues of creditors other than micro enterprises and small enterprises	68.38	757.69	242.23	66.46	-	-	1,164.76
Total	68.38	985.91	246.52	66.46	-	-	1,387.27

DHC
LP

Sureksha Diagnostic Private Limited

CIN:U85110WB2006PTC103266

Notes forming part of the Standalone Financial Statements as at and for the year ended March 31, 2023

(all amounts in INR Lacs, unless stated otherwise)

10 Other Current Liabilities

Particulars	As at March 31, 2023	As at March 31, 2022
Security deposit received from collection centres	65.93	85.53
Capital creditors	170.45	23.20
Advance from Customers	12.18	85.87
Interest accrued but not due	6.69	7.37
Employee Benefits Payable	489.94	330.81
Statutory Dues payable	80.35	133.70
Total Other current liabilities	826.54	626.48

11 Short-Term Provisions

Particulars	As at March 31, 2023	As at March 31, 2022
Provision for income tax (net of advance tax amounting to Rs Nil (March 31, 2022 is Rs 1,549.63 w/o))	-	114.21
Provision for Dividend of Equity & Preference Shares	0.00	0.00
Defined Benefit - Leave	7.87	5.38
Total	7.87	129.59

DHS
ur

12 Property, Plant & Equipment And Capital Work In Progress

Particulars	Property, Plant and Equipment										Capital Work In Progress	
	Land- Freehold	Buildings	Plant & Machinery	Computer Hardware	Furniture and fixtures	Laboratory Equipment	Vehicles	Computer Server	Office Equipment	Total		
Gross Block												
As at March 31, 2021	79.26	974.67	1,001.35	651.34	3,499.58	12,358.46	364.47	60.32	335.23	19,324.68	0.86	
Additions	-	10.40	97.60	53.11	194.36	634.21	42.12	-	30.10	1,061.90	737.38	
Disposals	-	-	6.27	-	-	340.24	29.80	-	-	376.31	-	
Transfer	-	-	19.25	27.12	446.98	133.88	-	-	1.70	628.93	(628.93)	
As at March 31, 2022	79.26	985.07	1,111.93	731.57	4,140.92	12,786.31	376.79	60.32	367.03	20,639.20	109.31	
Additions	-	-	34.25	19.22	147.18	858.65	21.30	-	28.89	1,109.49	360.35	
Disposals	-	-	129.16	37.93	97.12	358.91	13.77	17.67	12.77	667.33	-	
Transfer	-	-	6.61	0.84	221.17	1.77	-	-	0.19	230.58	(230.58)	
As at March 31, 2023	79.26	985.07	1,023.63	713.70	4,412.15	13,287.82	384.32	42.65	383.34	21,311.94	239.08	
Accumulated Depreciation												
As at March 31, 2021	-	32.69	588.40	582.17	1,447.98	4,538.34	169.20	56.97	217.62	7,633.37	-	
Charge for the year	-	15.58	88.02	43.58	327.53	885.56	41.72	0.26	48.71	1,450.96	-	
Disposals	-	-	4.41	-	-	174.70	21.32	-	-	200.43	-	
As at March 31, 2022	-	48.27	672.01	625.75	1,775.51	5,249.20	189.60	57.23	266.33	8,883.90	-	
Charge for the year	-	15.60	98.23	34.54	372.12	914.87	46.19	0.16	40.41	1,522.12	-	
Disposals	-	-	99.12	35.82	65.37	201.14	11.17	16.77	10.69	440.08	-	
As at March 31, 2023	-	63.87	671.12	624.47	2,082.26	5,962.93	224.62	40.62	296.05	9,965.94	-	
Net Block												
As at March 31, 2022	79.26	936.80	439.92	105.82	2,365.41	7,537.11	187.19	3.09	100.70	11,755.30	109.31	
As at March 31, 2023	79.26	921.20	352.51	89.23	2,329.89	7,324.89	159.70	2.03	87.29	11,346.00	239.08	

12.1 Capital Work in Progress (CWIP) ageing schedule

As at March 31, 2023

Particulars	Amount in CWIP for the period of				
	Less than 1 year	1-2 years	2-3 years	More than 3	Total
Project 1	47.41	-	-	-	47.41
Project 2	191.67	-	-	-	191.67
Total	239.08	-	-	-	239.08

As at March 31, 2022

Particulars	Amount in CWIP for the period of				
	Less than 1 year	1-2 years	2-3 years	More than 3	Total
Project 1	109.31	-	-	-	109.31
Total	109.31	-	-	-	109.31

12.2 For assets pledged as security refer note 5.

12.3 The Company has created a first and exclusive charge by way of mortgage over its entire land and building along with hypothecation of certain medical equipments having a gross block value of Rs. 5,896.20 lacs (Previous year Rs. 3,998.25 lacs) and net block of Rs. 3,785.37 lacs (Previous year Rs. 2,826.16 lacs) against personal loan taken by the directors (Refer note 38).

Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Financial Statements as at and for the year ended March 31, 2023

(all amounts in INR Lacs, unless stated otherwise)

13 Intangible Assets

Particulars	Other Intangible Assets		Intangible assets under development
	Computer software	Total	
Gross Block			
As at March 31, 2021	433.45	433.45	15.05
Additions	10.57	10.57	-
Transfers	15.05	15.05	(15.05)
As at March 31, 2022	459.07	459.07	-
Additions	5.39	5.39	-
Deletion	4.30	4.30	-
Transfers	-	-	-
As at March 31, 2023	460.16	460.16	-
Accumulated Amortisation			
As at March 31, 2021	225.52	225.52	-
Charge for the year	58.17	58.17	-
As at March 31, 2022	283.69	283.69	-
Charge for the year	35.96	35.96	-
Deletion	3.56	3.56	-
As at March 31, 2023	316.09	316.09	-
Net Block			
As at March 31, 2022	175.38	175.38	-
As at March 31, 2023	144.07	144.07	-

DHE
UP

14 Non-Current Investments

Particulars	As at March 31, 2023	As at March 31, 2022
Long Term Investment		
Investment in LLP's		
Investment in Suraksha Speciality LLP (Refer note 33)	50.00	15.50
Total	50.00	15.50
Aggregate amount of Unquoted Investments	50.00	15.50

(a) Details of Investment in Limited Liability Partnership

Investment in Suraksha Speciality LLP

Name of Partners

Suraksha Diagnostic Private Limited

Dr. Somnath Chatterjee

Total Capital of LLP - Rs.50.00 lacs (Previous Year - Rs.15.50 lacs)

Share of Profit (%)

99.99%

0.01%

Share of Profit (%)

99.99%

0.01%

15 Long-Term Loans and Advances

Particulars	As at March 31, 2023	As at March 31, 2022
Unsecured, considered good		
Prepaid Rent on Medical Equipments (Refer note 34)	128.93	156.79
Loan to Suraksha Speciality LLP (Refer note 33)	98.08	-
Capital Advances (Refer note 32)	24.50	40.27
Income Tax Refund	32.12	-
Advance Income Tax (Net of provision of Rs.357.58 Lacs (March 31, 2022 is Nil)	181.68	-
Total	465.31	197.06

16 Other Non-Current Assets

Particulars	As at March 31, 2023	As at March 31, 2022
Deposits with banks (Refer Note 16.1 below)	769.34	4,744.61
Security Deposits	825.04	740.20
Other Advances (Refer Note 32)	150.00	150.00
Total	1,744.38	5,634.81

16.1 Bank deposits of INR. 442.86 Lacs (Previous year Rs.444.71 Lacs) has been pledged by way of security for loan granted to the Company or bank guarantee given, which are not encashable within next year.

17 Inventories

Particulars	As at March 31, 2023	As at March 31, 2022
At cost or net realisable value, whichever is lower		
Consumable Stores	661.45	622.53
Total	661.45	622.53

DHC
UR

18 Trade Receivables

Particulars	As at March 31, 2023	As at March 31, 2022
- Trade Receivables considered good - Secured	-	-
- Trade Receivables considered good - Unsecured	558.44	756.70
- Trade Receivables - considered doubtful - Unsecured	163.29	163.29
	721.73	919.99
Less: Provision for doubtful debts	163.29	163.29
Total	558.44	756.70
Trade receivables include debts due by:		
Related Parties (Refer note 33)	148.11	125.38
Others	410.33	631.52
Total	558.44	756.70

18.1

Particulars	Outstanding from due date of payment as on March 31, 2023						Total
	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed							
- considered good	5.64	457.59	71.60	0.03	23.58	-	558.44
- considered doubtful	-	-	-	35.92	67.76	59.61	163.29
	5.64	457.59	71.60	35.95	91.34	59.61	721.73
Less: Provision for doubtful Debts	-	-	-	(35.92)	(67.76)	(59.61)	(163.29)
	5.64	457.59	71.60	0.03	23.58	-	558.44
Total	5.64	457.59	71.60	0.03	23.58	-	558.44

Particulars	Outstanding from due date of payment as on March 31, 2022						Total
	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed							
- considered good	226.89	307.00	194.53	19.20	9.28	-	756.70
- considered doubtful	-	-	-	124.02	39.27	-	163.29
	226.89	307.00	194.53	143.22	48.55	-	919.99
Less: Provision for doubtful Debts	-	-	-	(124.02)	(39.27)	-	(163.29)
	226.89	307.00	194.53	19.20	9.28	-	756.70
Total	226.89	307.00	194.53	19.20	9.28	-	756.70

19 Cash and Bank Balances

Particulars	As at March 31, 2023	As at March 31, 2022
Cash and Cash Equivalents		
Cash in hand (including in digital form)	55.77	44.41
In Current Accounts	119.03	213.61
Other Bank Balances		
Deposits with maturity period more than three months and less than twelve months (including accrued interest)	5,022.12	25.00
Total	5,196.92	283.02

20 Short-Term Loans and Advances

Particulars	As at March 31, 2023	As at March 31, 2022
Prepaid expenses	146.10	312.49
Prepaid Rent on Medical Equipments (Refer Note 34)	27.86	27.86
Other loans and advances		
Advance to Suppliers		
- Related Parties (Refer Note 33)	-	3.45
- Others	70.30	166.39
Other Advances		
- Others	0.62	6.50
Total	258.68	523.94

DHS
UP

Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Standalone Financial Statements as at and for the year ended March 31, 2023

(all amounts in INR Lacs, unless stated otherwise)

21 Revenue From Operations:

Particulars	For the year ended	
	Mar-23	Mar-22
Sale of services		
Diagnostic Service Charges	19,050.99	22,319.25
Total	19,050.99	22,319.25

22 Other Income

Particulars	For the year ended	
	Mar-23	Mar-22
<u>Interest income on</u>		
Fixed Deposit	253.69	163.40
Income Tax Refund	-	17.73
Suraksha Speciality LLP (Refer Note 33)	2.59	-
Profit on sale of Investments	-	0.29
Dividend on Mutual Fund	-	0.64
Liabilities/Provisions no longer required, written back	15.73	37.07
Miscellaneous Income	10.09	11.21
Total	282.10	230.34

23 Cost of Materials Consumed

Particulars	For the year ended	
	Mar-23	Mar-22
Inventory at the beginning of the year	622.53	444.50
Add: Purchases	2,714.30	6,218.52
	3,336.83	6,663.02
Less: Inventory at the closing of the year	661.45	622.53
Total	2,675.38	6,040.49

DHS
UP

24 Employee Benefits Expense

Particulars	For the year ended	
	Mar-23	Mar-22
Salaries and wages (Inclusive of Director's Remuneration)	3,734.79	3,152.56
Contribution to provident and other funds (Refer Note 31)	218.54	188.13
Gratuity expenses (Refer Note 31)	41.88	31.48
Staff welfare expenses	56.09	41.77
Total	4,051.30	3,413.94

25 Finance Cost

Particulars	For the year ended	
	Mar-23	Mar-22
Interest expense :		
on medical equipment / car term loan	118.00	130.99
on working capital term loan	10.96	21.57
Bank charges	49.85	57.81
Total	178.81	210.37

26 Depreciation and amortisation expense

Particulars	For the year ended	
	Mar-23	Mar-22
Depreciation on Property, Plant and Equipment (Refer note 12)	1,522.12	1,450.96
Amortisation of Intangible Assets (Refer note 13)	35.96	58.17
Total	1,558.08	1,509.13

27 Other Expenses

Particulars	For the year ended	
	Mar-23	Mar-22
Doctors Professional Fees	2,704.09	2,097.33
Sample Testing, Collection and Logistic Charges	241.28	263.35
Commission to Collection Centers	189.97	146.72
Repairs and Maintenance:		
Machinery (including medical equipment)	824.18	839.75
Building	27.98	49.71
Others	117.54	78.92
Donation	-	1.35
Office Administration Expenses	576.19	479.80
Advertisement and sales promotion	443.96	282.19
Electricity Charges	641.11	522.30
Expense relating to Acquisition and Valuations	-	88.45
Travelling and Conveyance Charges	145.90	195.64
Telephone and Internet Charges	91.74	91.95
Insurance Charges	98.82	79.96
Information Technology Expenses	499.23	301.47
CSR Expense	40.42	33.72
Rent (Refer Note 34)	1,990.37	1,793.46
Rent on Medical Equipments (Refer Note 34)	228.82	68.39
Rates and Taxes	57.67	73.31
Auditors Remuneration (Refer Note 29)	17.70	14.30
Legal and Professional Fees	207.39	169.72
Membership and subscription expenses	77.69	83.82
Freight and Other Charges	18.44	18.54
Loss on disposal of property, plant and equipment	160.23	141.48
Miscellaneous Expenses	124.81	140.66
Total	9,525.53	8,056.29

DHS
UP

28 Earning Per Share

Particulars	For the year ended	
	Mar-23	Mar-22
Net Profit attributable to Shareholders	1,138.83	2,375.10
Basic Earnings per Share		
Weighted average number of ordinary shares (No. in lacs)	6.90	6.90
Nominal value of ordinary share (in Rs. Per share)	100.00	100.00
Basic earnings for ordinary shares (in Rs. per share)	165.05	344.22
Diluted earnings per share		
Weighted average number of ordinary shares	6.90	6.90
Weighted average number of ordinary shares on account of Convertible Preference Shares	1.63	1.83
	8.53	8.53
Nominal value of ordinary share (in Rs. Per share)	100.00	100.00
Diluted earnings for ordinary shares (in Rs. per share)	133.53	278.49

29 Payment to Auditors

Particulars	For the year ended	
	Mar-23	Mar-22
As Statutory Auditors :		
Audit Fees	17.70	12.50
In Other Capacity:		
Other Services	-	1.80
Total	17.70	14.30

30 Corporate Social Responsibility

Particulars	For the year ended	
	Mar-23	Mar-22
a) Gross amount to be spent by the Company during the year	40.42	61.09
b) Amount spent during the period		
(i) Construction/ acquisition of any asset	-	-
(ii) On purpose other than (i) above	40.42	61.10
c) Amount unspent during the period*	-	-
d) Nature of CSR activities	Socio-Economic Development, Healthcare, Education	Socio-Economic Development, Healthcare, Education

DK
UR

31 Employee benefits

in accordance with the Accounting Standard-15 'Employee Benefits', the Company has calculated the various benefits provided to employees as under:

A. Defined contribution plans

During the period the Company has recognized the following amounts in the Statement of profit and loss:-

Particulars	For the year ended 31	For the year ended 31
	March 2023	March 2022
Employers Contribution to Provident fund	165.58	142.67
Employers Contribution to Employee State Insurance	52.96	45.46
	218.54	188.13

B. Defined benefit plans

Gratuity plan

The Company has taken up a Group Gratuity Scheme with Life Insurance Corporation of India (LIC), 'Suraksha Diagnostic Private Limited Employees' Gratuity Fund' to meet its obligation towards gratuity.

The following tables summarize the components of net benefit expense recognized in the statement of profit and loss and the funded status and amounts recognized in the balance sheet for the plan.

(i) Actuarial assumptions:

The principle assumptions used in determining gratuity obligations for company's plan are shown below

Particulars	For the year ended 31	For the year ended 31
	March 2023	March 2022
Discount rate (per annum)	7.25%	7.30%
Expected Rate of increase in compensation levels	5.25%	5.25%
Expected rate of return on plan assets	7.01%	6.75%
Mortality Rate	LIC(2006-08) ultimate	Indian Assured Lives Mortality (2012-2014)
Retirement age	60 Years	60 Years
Average attained age	33.75 Years	33.32 Years
Withdrawal Rate (based on age %(age))		
- Upto 30 years	3%	3%
- 31 to 44 years	2%	2%
- 44 years & above	1%	1%

The estimates of future salary increase considered in actuarial valuation, takes account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

(ii) Amount to be recognized in Balance Sheet:

Particulars	As at	As at
	31 March 2023	31 March 2022
Present value of defined benefit obligations	(4.19)	1.05
Net (asset) / liability arising from defined benefit obligations	(4.19)	1.05

(iii) Expenses recognized in Statement of Profit and Loss:

Particulars	For the year ended 31	For the year ended 31
	March 2023	March 2022
Current service cost	46.05	41.19
Interest cost	18.99	17.30
Expected return on plan assets	(19.71)	(17.96)
Net actuarial loss/(gain) recognized during the year	(3.45)	(9.05)
Total charge to Statement of Profit and Loss	41.88	31.48

DTC
UP

Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Standalone Financial Statements as at and for the year ended March 31, 2023
(all amounts in INR Lacs, unless stated otherwise)

(iv) Changes in the present value of the defined benefit obligation in respect of Gratuity are as follows:

Particulars	As at	As at
	31 March 2023	31 March 2022
Present value obligation as at the beginning of the year	264.68	250.76
Interest cost	18.98	17.30
Current service cost	46.05	41.18
Benefits paid	(37.61)	(30.39)
Actuarial gain on obligations (including Rs. 2.70 lacs pertaining to earlier years)	(6.15)	(14.17)
Present value obligation as at the end of the year	285.96	264.68

(v) Changes in the fair value of plan assets:

Particulars	As at	As at
	31 March 2023	31 March 2022
Balance at the beginning of the year	263.63	262.51
Expected Return on plan assets	19.71	17.96
Actuarial gain on plan assets	-	(5.12)
Actual Company Contributions	44.42	18.87
Benefits paid	(37.61)	(30.39)
Balance at the end of the year	290.15	263.63

Actual Return on Plan Assets	19.71	12.83
-------------------------------------	--------------	--------------

(vi) Net assets/liability and actuarial experience gain/(loss) for present benefit obligation ('PBO') and plan

Particulars	As at	As at
	31 March 2023	31 March 2022
Present value of obligation	285.96	264.68
Less: Fair Value of Plan assets	290.15	263.63
Net (assets)/liability	(4.19)	1.05
Experience (gain)/loss on PBO	-	(0.75)
Experience gain/(loss) on plan assets	-	(5.12)

(vii) Major Category of Plan Assets as a % of total Plan Assets

	As at	As at
	31 March 2023	31 March 2022
Funds managed by Insurer	100%	100%

(viii) The Company has contributed Rs.49.30 lacs (Previous year Rs.44.42 lacs) towards gratuity for next financial year.

DHS
UP

32 Contingencies & Commitments

(To the extent not provided for)

i. Contingent Liability

Particulars	As at 31-Mar-2023	As at 31-Mar-2022
Claims against the Company not acknowledged as debt (Refer note (a) below)	150.00	150.00
Corporate Guarantee to financial institution against loan taken by directors (Refer note (b) below)	6,700.00	6,700.00
	6,850.00	6,850.00

- (a) The Company had given an earnest money deposit by way bank guarantee of Rs.150.00 lacs (Previous year Rs.150.00 lacs) to Bihar State Health Society in 2014-15 which had been encashed by the other party on grounds of non-compliance of the term of agreement. The Company has filed writ petition before the Patna High Court which is pending disposal. The Company is hopeful of succeeding in appeal and as such does not expect an significant liability to materialise.
- (b) The Company has given guarantee of Rs. 6,700 lacs to the extent of security provided to Kotak Mahindra Investments Ltd. against personal loan taken by Directors of the Company for Rs. 6,700 lacs (Previous Year: Rs. 6,700 lacs). The Company has created a first and exclusive charge by way of mortgage over its entire land and building along with hypothecation of certain medical equipment owned by the Company amounting to Rs 3,231.99 lacs (Previous Year: Rs. 2,826.16 lacs) (Refer note 38).

ii. Commitments

Particulars	As at 31-Mar-2023	As at 31-Mar-2022
Estimated amount of contract remaining to be executed on capital account	162.33	94.10
Less: Capital Advance	24.50	40.27
Total	137.83	53.83

DHC
UP

33 Related party Disclosures as per AS 18

(A) List of Related parties :

<u>Name of Related Party</u>	<u>Description of relationship</u>
Suraksha Speciality LLP	Subsidiary of the Company (control exists)
Suraksha Salvia LLP	Subsidiary of Suraksha Speciality LLP (control exists)
Dr Somnath Chatterjee (Director)	Key Managerial Person (KMP)
Ritu Mittal (Director)	Key Managerial Person (KMP)
Suraksha Diagnostic & Eye Centre Private Limited	Enterprises owned or significantly influenced by KMP
Oscar Enclave Private Limited	Enterprises owned or significantly influenced by KMP
R.A. Enterprises	Enterprises owned or significantly influenced by KMP
Kejriwal Constructions	Enterprises owned or significantly influenced by KMP
Sahayta Clinic LLP	Enterprises owned or significantly influenced by KMP
Suresh Enterprise	Enterprises owned or significantly influenced by KMP
Kejriwal Electronics Ltd	Enterprises owned or significantly influenced by KMP
Calcutta Cosmopolitan Club Ltd	Enterprises owned or significantly influenced by KMP
Pragati Kejriwal	Relative of KMP
Raghavi Mittal	Relative of KMP
Dr Aparajita Chatterjee	Relative of KMP
Dr Tandra Chatterjee	Relative of KMP

(B) Details of transactions with Related Parties

Particulars	For the period ended	
	March 31, 2023	March 31, 2022
Sale of Services		
Suraksha Diagnostic & Eye Centre Private Limited	343.37	244.10
Suraksha Salvia LLP	13.06	-
Total	356.43	244.10
Purchase of Consumables		
R.A. Enterprise	1,472.30	1,536.06
Kejriwal Electronics Ltd	0.58	-
Total	1,472.88	1,536.06
Rent Expense		
Oscar Enclave Private Limited	447.10	444.79
Kejriwal Constructions	62.19	62.19
Suresh Enterprise	34.27	31.15
Total	543.56	538.13
Sales Promotion expenses to relative of KMP		
Raghavi Mittal	0.50	0.90
Total	0.50	0.90
Professional Fees to relative of KMP		
Pragati Kejriwal	9.00	6.00
Dr Aparajita Chatterjee	5.13	-
Dr Tandra Chatterjee	0.25	-
Total	14.38	6.00
Guarantee Fee		
Dr. Somnath Chatterjee	-	2.75
Ritu Mittal	-	5.50
Total	-	8.25
Commission Paid		
Sahayta Clinic LLP	0.63	0.17
Total	0.63	0.17
Sponsorship Charges		
Calcutta Cosmopolitan Club Ltd	1.18	-
Total	1.18	-
Loan Interest		
Suraksha Speciality LLP	2.59	-
Total	2.59	-
Loan to LLP		
Suraksha Speciality LLP	95.76	-
Total	95.76	-
Advances to LLP		
Suraksha Salvia LLP	6.97	6.82
Total	6.97	6.82
Investment made in LLP		
Suraksha Speciality LLP	34.50	5.00
Total	34.50	5.00

4/11
4/11

Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Standalone Financial Statements as at end for the year ended March 31, 2023

(all amounts in INR Lacs, unless stated otherwise)

(C) Receivable from & Payable to Related Parties are set out below:

Particulars	As at March 31, 2023	As at March 31, 2022
Receivable from:		
Suraksha Diagnostic & Eye Centre Private Limited (Trade Receivable)	136.38	125.38
Suraksha Salvia LLP (Other Advances)	13.80	6.82
Suraksha Salvia LLP (Trade Receivable)	11.75	-
Suraksha Speciality LLP (Loan including Interest)	98.08	-
Oscar Enclave Private Limited (Security Deposit)	114.60	114.60
Suresh Enterprise (Security Deposit)	12.00	12.00
Suraksha Diagnostic & Eye Centre Private Limited (Advances to Suppliers)	-	3.44
Sahayata Clinic LLP (Advances from Suppliers)	-	0.01
Ritu Mittal (Other Receivable)	-	5.50
Somnath Chatterjee (Other Receivable)	-	2.75
Total	386.59	270.50
Payable for:		
R.A. Enterprise (Trade Payable)	279.58	238.59
Oscar Enclave Pvt Ltd (Trade Payable)	34.25	33.82
Kejriwal Constructions (Trade Payable)	4.74	4.74
Kejriwal Electronics Ltd (Trade Payable)	0.02	-
Suresh Enterprise (Trade Payable)	2.61	2.36
Dr Aparajita Chatterjee	0.00	-
Pragati Kejriwal	0.68	-
Ritu Mittal	7.88	7.88
Somnath Chatterjee	7.88	7.88
Sahayata Clinic LLP	0.10	-
Total	337.74	295.39

(D) Remuneration of Key Management Personnel

The remuneration of key management personnel and a relative of key management personnel of the Company are set out below in aggregate for each of the categories specified in AS 18 'Related party disclosures'.

Particulars	For the year ended	
	31 March 2023	31 March 2022
Salaries and Allowances		
Dr. Somnath Chatterjee	144.00	144.00
Ritu Mittal	144.00	144.00
Total Director's Remuneration	288.00	288.00

Notes:

- There are no provisions for doubtful debts/ advances or amounts written off or written back for debts due from/ debts to related parties.
- Remuneration excludes provision for gratuity and leave as the incremental liabilities has been accounted for as the Company as a whole.

DHC
UP

34 Leases**Operating lease: Company as lessee**

- a. The Company's significant leasing arrangements are in respect of operating leases for -
Premises (office, diagnostic centre's etc.) - These leasing arrangements are cancellable in nature as per the terms of individual agreement and are usually renewable on mutual consent basis. The aggregate lease rentals payable are charged as 'Rent' under Note 27.
- b. Medical Equipment - The Company has entered into leasing agreement for certain medical equipments with a vendor. These non cancellable leases are for a period of 7 years. The aggregate lease rentals payable are charged as 'Rent on medical equipment' under Note 27.

Future minimum rentals payments under non-cancellable operating leases are as follows:

	31 March 2023	31 March 2022
Within one year	27.86	27.86
After one year but not more than five years	111.43	111.43
More than five years	17.50	45.35
Total	156.79	184.64

35 Segment Reporting**(A) Information about primary segments**

The primary segment of the Company is business segment which comprises of carrying on the business of diagnostic centers for providing various pathology and radiology services. The entire operations are governed by the same set of risks and returns and hence is considered as representing a single business segment. As the Company operates in a single primary business segment, no separate segment information has been disclosed.

(B) Segment information for secondary segment reporting (by geographical segment)

The Company's entire revenue comes from customers located in India, therefore no separate geographical segments have been presented.

DS
60

36 Ratio Analysis and its Elements

Ratios	Numerator	Denominator	March 31, 2023		March 31, 2022		Ratio as on		Variation	Reason (if variation is more than 25%)
			Numerator	Denominator	Numerator	Denominator	March 31, 2023	March 31, 2022		
Current Ratio	Current Assets	Current Liabilities	6,675.49	2,821.07	2,186.19	2,808.16	2.37	0.78	203.85%	Refer Note 1
Debt-Equity Ratio	Debt (Borrowing)	Total Equity	1,400.56	16,140.24	1,901.94	15,001.41	0.09	0.13	(30.77%)	Refer Note 2
Debt Service Coverage ratio	Earnings before interest, depreciation and taxes (Profit)	Interest Payments + Principal	3,080.88	825.78	5,038.87	834.36	3.73	6.04	(38.25%)	Refer Note 1
Return on Equity ratio	Profit for the year	Total Equity	1,138.83	16,140.24	2,375.10	15,001.41	7.06%	15.83%	(56.25%)	Refer Note 1
Inventory Turnover ratio	Cost of Materials Consumed	Average Inventory	2,675.38	641.99	6,040.49	533.52	4.17	11.32	(63.16%)	Refer Note 1
Trade Receivable Turnover Ratio	Revenue from operations	Average Trade Receivable	19,050.99	657.57	22,319.25	678.12	28.97	32.91	(11.97%)	NA
Trade Payable Turnover Ratio	Purchases	Average Trade Payable	2,714.30	1,407.39	6,218.52	1,323.79	1.93	4.70	(58.94%)	Refer Note 1
Net Capital Turnover Ratio	Revenue from operations	Total Equity	19,050.99	16,140.24	22,319.25	15,001.41	1.18	1.49	(20.81%)	NA
Net Profit ratio	Profit for the year	Revenue from	1,138.83	19,050.99	2,375.10	22,319.25	5.96%	10.64%	(45.45%)	Refer Note 1
Return on Capital Employed	Profit Before Tax + Finance cost	Equity + Debt (Borrowings)	1,522.80	17,540.80	3,529.74	16,903.34	8.68%	20.88%	(57.14%)	Refer Note 1
Return on Investment	Interest income on fixed deposits, bonds and debentures + Dividend Income + Profit on sale of investments	Current Investments + Non current Investments + Other Bank Balances	253.69	5,841.45	164.33	4,785.11	4.34%	3.43%	33.33%	Refer Note 3

Notes:

- 1) Decrease in revenue from operation impacted the various operating activities and profits for the year. Country was impacted by COVID in previous year resulted in increase in revenue from operations unlike current year.
- 2) Variation mainly on account of decrease in debt due to repayments as per terms of borrowings and increase in total equity on account of profit earned for the year.
- 3) Due to increase in FD rates in the market, there is an increase in Return on Investment.

DH
UP

37 Additional regulator information required by Schedule III

- a. The title deeds of all the immovable properties, (other than immovable properties where the Company is the lessee and the lease agreements are duly executed in favour of the Company) disclosed in the financial statements included in property, plant and equipment and capital work-in progress are held in the name of the Company as at the balance sheet date.
- b. The Company does not have any transactions or balances with companies struck off under section 248 of the Companies Act, 2013 or Section 580 of the Companies Act 1956.
- c. The Company has complied with the requirement with respect to number of layers as prescribed under section 2(87) of the Companies Act, 2013 read with the Companies (Restriction on number of layers) Rules, 2017.
- d. The Company does not have any benami property held in its name. No proceedings have been initiated on or are pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.
- e. The Company does not have any charges or satisfaction of charges which are yet to be registered with Registrar of Companies beyond the statutory period.
- f. The Company has not been declared wilful defaulter by any bank or financial institution or other lender or government or any government authority.
- g. The Company does not have any such transaction which is not recorded in the books of account that has been surrendered or disclosed as income during the year in the tax assessment under the Income Tax Act, 1961.
- h. The Company has not traded or invested in Crypto currency or Virtual Currency during the year.
- i. Utilisation of Borrowed funds and share premium:

- The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (intermediaries) with the understanding that the intermediary shall:
- (a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
- (b) Provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
- (a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
- (b) Provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries
- j. Details of Loan given, investment made and Guarantee given covered u/s 186 (4) of the Companies Act, 2013
- (i) Loan given by the Company to body corporate/ others as at March 31, 2023. (Refer note 15)
- (ii) Investment made by the Company as at March 31, 2023. (Refer note 14)
- (iii) Guarantee has been given by the Company as at March 31, 2023 (Refer note 32)

- 38 As stated in note 32 (i) (b), the Company has given guarantee and created charge on certain of its items of Property, Plant and Equipment as security for a personal loan of Rs. 6,700 lacs taken by the wholetime directors of the Company. While this transaction occurred in the year ended 31st March 2022, it was based on a bonafide belief to be in compliance with section 185 of the Companies Act 2013 considering a legal opinion obtained by the lender. During the current year, as pointed out by the statutory auditors, the Company acknowledges that the transaction of giving guarantee and security for a personal loan taken by the wholetime directors of the Company is a contravention of section 185 of the Companies Act 2013. Subsequent to the year end, the Company has, on a suo moto basis, made a compounding application for the same. Adjudication of the said application is awaited. Accordingly, the impact on the standalone financial statements, if any, will be given upon adjudication of the compounding application.

- 39 Subsequent to the year end, the Company and the statutory audit team received multiple emails alleging financial fraud, liquidation of monies etc., by the Company/directors over the period from 2020 to 2023. Allegations covered advancing amounts to an employee for inappropriate purposes, payments to certain vendors without receipt of related goods/services, payment made to doctors and debit of personal expenses as sales promotion expenses. Despite the fact that Rule 7 of the Companies (Meetings of Board and its Powers) Rules, 2014 regarding vigil mechanism is not applicable to the Company, the Company appointed an independent Chartered Accountant firm to investigate the allegations. The said firm has submitted its report covering allegations made up to the date of the report and concluding that no instances of fraudulent transactions were noted though has highlighted certain violations of the Goods and Service Tax Act 2017, which the Company is in the process of addressing. The Company has filed an FIR with the Bidhannagar cyber crime Police station relating to defamatory emails and investigation is in progress.

40 Previous year figures

Previous year's figures have been regrouped/re-arranged wherever considered necessary.

DHK
UP

Suraksha Diagnostic Private Limited

CIN: U85110WB2005PTC102265

Notes forming part of the Standalone Financial Statements as at and for the year ended March 31, 2023
(all amounts in Rs. unless stated otherwise)

DHS
LP

for and on behalf of the Board of Directors of
Suraksha Diagnostic Private Limited



Dr Somnath Chatterjee
Director
DIN: 00137075



Ritu Mittal
Director
DIN: 00165688

Place: Kolkata
Date: 31/03/2024